Furthermore, the hepatitis B X-interacting protein, HBXIP, also termed late endosomal/lysosomal adaptor, MAPK and mTOR activator 5 (LAMTOR5), was claimed to induce the upregulation of glucose transporter 1 (GLUT1) through the NF-κB pathway during hepatic cancer development [168]. This evidence concerns the gene LAMTOR5 and liver cancer.